檢索結果 - Chandiwana, David

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom 由 Suri, Gaurav, Chandiwana, David, Lee, Adam, Mistry, Rohit

獲取全文 獲取全文 獲取全文

Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews 由 Romano, Carla, Harris, Nimanee, Gnanasakthy, Ari, D’Alessio, Denise, Chandiwana, David

獲取全文 獲取全文 獲取全文

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer 由 Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel

獲取全文 獲取全文 獲取全文

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer 由 Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio

獲取全文 獲取全文 獲取全文

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom 由 Amdahl, Jordan, Diaz, Jose, Sharma, Arati, Park, Jinhee, Chandiwana, David, Delea, Thomas E.

獲取全文 獲取全文 獲取全文

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil 由 Buehler, Anna Maria, Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Igho-Osagie, Ebuwa

獲取全文

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer? 由 Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Shor, Anastasiya, Tremblay, Gabriel

獲取全文 獲取全文 獲取全文

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... 由 Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang

獲取全文 獲取全文 獲取全文

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer 由 Turner, Stuart, Chia, Stephen, Kanakamedala, Hemanth, Hsu, Wei‐Chun, Park, Jinhee, Chandiwana, David, Ridolfi, Antonia, Yu, Chu‐Ling, Zarate, Juan Pablo, Rugo, Hope S.

獲取全文 獲取全文 獲取全文

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer 由 Fasching, Peter A, Delea, Thomas E, Lu, Yen-Shen, De Boer, Richard, Hurvitz, Sara A, Moynahan, Aaron, Chandiwana, David, Lanoue, Brad, Hu, Huilin, Thuerigen, Astrid, O’Shaughnessy, Joyce

獲取全文 獲取全文 獲取全文

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results f... 由 Harbeck, Nadia, Franke, Fabio, Villanueva-Vazquez, Rafael, Lu, Yen-Shen, Tripathy, Debu, Chow, Louis, Babu, Govind K, Im, Young-Hyuck, Chandiwana, David, Gaur, Anil, Lanoue, Brad, Rodriguez-Lorenc, Karen, Bardia, Aditya

獲取全文 獲取全文 獲取全文

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer 由 Tripathy, Debu, Curteis, Tristan, Hurvitz, Sara, Yardley, Denise, Franke, Fabio, Babu, K. Govind, Wheatley-Price, Paul, Im, Young-Hyuck, Pencheva, Radost, Eddowes, Lucy A., Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Lanoue, Brad, Harbeck, Nadia

獲取全文 獲取全文 獲取全文

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study 由 Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd

獲取全文 獲取全文 獲取全文